Epizyme Inc (NASDAQ:EPZM) shares rose 7.5% on Thursday . The company traded as high as $12.42 and last traded at $12.32. Approximately 841,450 shares changed hands during mid-day trading, a decline of 2% from the average daily volume of 855,643 shares. The stock had previously closed at $11.46.

EPZM has been the topic of a number of recent analyst reports. Cowen reissued a “buy” rating and issued a $18.00 price objective on shares of Epizyme in a research note on Tuesday, February 26th. BidaskClub raised Epizyme from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Oppenheimer cut their price objective on Epizyme from $27.00 to $18.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 27th. ValuEngine downgraded Epizyme from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. Finally, Roth Capital reissued a “buy” rating on shares of Epizyme in a research note on Wednesday, February 27th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Epizyme presently has an average rating of “Buy” and an average price target of $18.90.

The firm has a market cap of $1.10 billion, a PE ratio of -7.05 and a beta of 3.08. The company has a quick ratio of 12.55, a current ratio of 12.55 and a debt-to-equity ratio of 0.03.

Epizyme (NASDAQ:EPZM) last released its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.07. The business had revenue of $7.89 million during the quarter, compared to analyst estimates of $1.13 million. As a group, equities research analysts predict that Epizyme Inc will post -1.98 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JGP Global Gestao de Recursos Ltda. grew its holdings in shares of Epizyme by 10.4% during the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 13,691 shares of the biopharmaceutical company’s stock worth $170,000 after purchasing an additional 1,293 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Epizyme by 16.9% during the 4th quarter. Legal & General Group Plc now owns 10,060 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 1,455 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Epizyme by 5.7% during the 1st quarter. The Manufacturers Life Insurance Company now owns 40,022 shares of the biopharmaceutical company’s stock worth $496,000 after purchasing an additional 2,152 shares in the last quarter. Metropolitan Life Insurance Co NY grew its holdings in shares of Epizyme by 18.3% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 19,570 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 3,029 shares in the last quarter. Finally, American International Group Inc. grew its holdings in shares of Epizyme by 13.0% during the 4th quarter. American International Group Inc. now owns 39,223 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 4,513 shares in the last quarter. 74.44% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.watchlistnews.com/epizyme-epzm-stock-price-up-7-5/3015079.html.

Epizyme Company Profile (NASDAQ:EPZM)

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

Featured Story: Determine Your Level of Risk Tolerance

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.